Alvotech Reports Record Results for 2024 and Provides Business Update
Total Revenues in 2024 reached $492 million, representing a 427% increase over…
Alvotech Acquires Xbranes R&D Operations in Swedenand Further Affirms its Global Leadership Positionin Biosimilars Development and Production
REYKJAVIK, Iceland and STOCKHOLM, March 20, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ:…
Alvotech Acquires Xbranes R&D Operations in Sweden and Further Affirms its Global Leadership Position in Biosimilars Development and Production
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and…
Teva and Alvotech Announce SELARSDI (ustekinumab-aekn) Injection Now Available in the U.S.
In October 2024, the U.S. Food and Drug Administration (FDA) approved SELARSDI™…
Alvotech Added to Nasdaq Biotech Index Effective Monday December 23, 2024
Addition is part of the annual reconstitution of the Nasdaq Biotech Index…
Alvotech Added to Nasdaq Biotech Index Effective Monday December 23, 2024
Addition is part of the annual reconstitution of the Nasdaq Biotech Index…